Greg Guyer Charles's most recent trade in Biomarin Pharmaceutical Inc. - Registered Shares was a trade of 30,880 Stock Option (Right to Buy Common Stock) done . Disclosure was reported to the exchange on March 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 30,880 | 30,880 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.44 per share. | 14 Mar 2025 | 20,127 | 67,528 (0%) | 0% | 69.4 | 1,397,619 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 13,310 | 80,838 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 71.28 per share. | 06 Mar 2025 | 7,034 | 87,655 (0%) | 0% | 71.3 | 501,355 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 71.16 per share. | 28 Feb 2025 | 4,287 | 94,689 (0%) | 0% | 71.2 | 305,063 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 11,040 | 79,949 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 9,660 | 89,609 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 9,367 | 98,976 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 66.37 per share. | 12 Nov 2024 | 5,278 | 68,909 (0%) | 0% | 66.4 | 350,324 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 56.00 per share. | 12 Nov 2024 | 55 | 74,187 (0%) | 0% | 56 | 3,080 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.44 per share. | 03 May 2024 | 4,440 | 74,132 (0%) | 0% | 82.4 | 366,034 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 68.64 per share. | 03 May 2024 | 245 | 78,572 (0%) | 0% | 68.6 | 16,818 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 23,630 | 23,630 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.87 per share. | 15 Mar 2024 | 20,424 | 78,327 (0%) | 0% | 83.9 | 1,712,961 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 10,550 | 98,751 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Greg Charles Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 20,840 | 72,854 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Greg Charles Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 9,063 | 81,917 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Guyer Greg Charles | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 6,284 | 88,201 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Greg Guyer Charles | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 11,840 | 52,014 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 69.23 per share. | 01 Dec 2023 | 133 | 40,174 (0%) | 0% | 69.2 | 9,208 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 93.30 per share. | 09 Aug 2023 | 5,360 | 40,041 (0%) | 0% | 93.3 | 500,109 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 95.45 per share. | 28 Apr 2023 | 4,302 | 45,401 (0%) | 0% | 95.5 | 410,626 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 66.88 per share. | 28 Apr 2023 | 239 | 49,703 (0%) | 0% | 66.9 | 15,984 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 20,320 | 20,320 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 8,900 | 51,320 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.74 per share. | 15 Mar 2023 | 1,856 | 49,464 (0%) | 0% | 87.7 | 162,845 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 62.41 per share. | 31 Dec 2022 | 252 | 42,420 (0%) | 0% | 62.4 | 15,727 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 96.56 per share. | 08 Aug 2022 | 6,205 | 42,168 (0%) | 0% | 96.6 | 599,155 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 26,520 | 26,520 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 11,040 | 52,976 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.27 per share. | 15 Mar 2022 | 920 | 52,056 (0%) | 0% | 78.3 | 72,008 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.35 per share. | 30 Apr 2021 | 3,986 | 41,695 (0%) | 0% | 78.3 | 312,303 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 62.41 per share. | 30 Apr 2021 | 221 | 45,681 (0%) | 0% | 62.4 | 13,792 | Common Stock |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 25,650 | 25,650 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Charles Greg Guyer | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 10,420 | 45,460 (0%) | 0% | 0 | Common Stock |